右旋普拉克索降低鼻息肉患者血液及组织嗜酸性粒细胞但未缩小息肉体积
本研究为6个月开放标签多中心研究,16例伴嗜酸性粒细胞增多的慢性鼻窦炎伴鼻息肉患者接受右旋普拉克索150mg每日两次治疗。结果显示血液嗜酸性粒细胞几何均值从0.525×10^9/L降至0.031×10^9/L(降幅94%,P<0.001),鼻息肉组织嗜酸性粒细胞从168个/HPF降至5个/HPF(降幅97%,P=0.001),但总息肉评分及其他临床终点无显著改善,药物耐受性良好。
要点
- 右旋普拉克索可显著降低血液及鼻息肉组织嗜酸性粒细胞水平。
- 嗜酸性粒细胞近乎消除并未带来息肉体积缩小或症状改善。
- 药物耐受性良好,未发生药物相关严重不良事件。
核心结论
- 右旋普拉克索治疗使外周血和鼻息肉组织嗜酸性粒细胞大幅降低。
- 尽管息肉嗜酸性粒细胞近乎消除,总息肉评分未降低,鼻部症状未改善。
研究设计与样本
- 6个月开放标签、多中心研究,纳入16例慢性鼻窦炎伴鼻息肉且绝对嗜酸性粒细胞计数≥0.300×10^9/L并可评估息肉组织嗜酸性粒细胞的受试者。
- 右旋普拉克索150mg每日两次口服,共同主要终点为基线至第6个月绝对嗜酸性粒细胞计数和总息肉评分的变化。
主要发现
- 16例中13例完成6个月治疗。
- 基线绝对嗜酸性粒细胞计数几何均值为0.525±0.465×10^9/L,治疗6个月后降至0.031±0.019×10^9/L,降幅94%(P<0.001)。
- 16例中10例在第6个月嗜酸性粒细胞计数降至≤0.020×10^9/L。
- 12例有基线和第6个月鼻息肉活检的受试者,组织嗜酸性粒细胞从平均168±134个/HPF降至5±2个/HPF(P=0.001),降幅97%。
- 总息肉评分无显著降低,其他临床终点无改善;药物耐受性良好,无药物相关严重不良事件。
关键数值与推荐
- 研究纳入标准为慢性鼻窦炎伴鼻息肉、绝对嗜酸性粒细胞计数≥0.300×10^9/L。
- 右旋普拉克索剂量为150mg每日两次,疗程6个月。
- 疗效评估指标包括绝对嗜酸性粒细胞计数、总息肉评分、鼻息肉组织嗜酸性粒细胞(个/HPF)及临床终点。
临床怎么用
- 右旋普拉克索可显著降低血液和息肉组织嗜酸性粒细胞,但本研究未观察到息肉体积或症状获益,暂不支持以缩小息肉为目标的临床使用。
- 嗜酸性粒细胞的近乎完全消除与息肉改善不相关,提示嗜酸性粒细胞可能并非鼻息肉生长的唯一驱动因素。
局限性
- 研究为开放标签、单臂设计,样本量小(16例),缺乏对照组。
- 组织嗜酸性粒细胞分析仅基于12例有配对活检的受试者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilia is a disease of the upper respiratory tract for which few therapies are available. Because the oral investigational drug dexpramipexole serendipitously decreased blood eosinophils in amyotrophic lateral sclerosis studies, we assessed its safety, eosinophil-lowering activity, and preliminary clinical efficacy in patients with CRSwNP and eosinophilia. METHODS: Sixteen subjects with CRSwNP, absolute eosinophil count (AEC) ≥ 0.300 × 109 /L, and polyp tissue eosinophils were evaluable for efficacy in a 6-month open-label, multi-center study of dexpramipexole 150 mg twice daily. The coprimary endpoints were change in AEC and change in total polyp score (TPS) from baseline to month 6, with additional clinical and histologic endpoints assessed. RESULTS: Thirteen of 16 subjects completed 6 months of dexpramipexole treatment. Geometric mean baseline AEC was 0.525 ± 0.465 eosinophils × 109 /L and decreased to 0.031 ± 0.019 after 6 months of dexpramipexole treatment, a 94% reduction (P < 0.001). Ten of 16 subjects had eosinophil counts reduced to ≤ 0.020 × 109 /L at month 6. In 12 subjects with nasal polyp biopsies at baseline and month 6, tissue eosinophils were reduced from a mean of 168 ± 134 to 5 ± 2 per high-power field (HPF) (P = 0.001), a 97% reduction from baseline. There was no significant reduction in TPS or improvement in other clinical endpoints. Dexpramipexole was well tolerated, with no drug-related serious adverse events. CONCLUSION: Dexpramipexole treatment produced profound eosinophil-lowering in peripheral blood and nasal polyp tissue. Despite the near-elimination of polyp eosinophils, decreased TPS and nasal symptom improvement were not observed. LEVEL OF EVIDENCE: 2 Laryngoscope, 129:E61-E66, 2019.
引用
- Laidlaw TM, Prussin C, Panettieri RA, et al. Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size. Laryngoscope. 2018. PMID: 30284267. doi:10.1002/lary.27564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。